Cancer statistics, 2012, CA: A Cancer Journal for Clinicians, vol.287, issue.suppl 5, pp.10-29, 2012. ,
DOI : 10.3322/caac.20138
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity, Cell, vol.147, issue.5, pp.992-1009, 2012. ,
DOI : 10.1016/j.cell.2011.11.016
Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes, International Journal of Cancer, vol.129, issue.2, 2011. ,
DOI : 10.1002/ijc.26471
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion, Science, vol.331, issue.6024, pp.1565-1570, 2011. ,
DOI : 10.1126/science.1203486
The immune score as a new possible approach for the classification of cancer, Journal of Translational Medicine, vol.10, issue.1, pp.1-4, 2012. ,
DOI : 10.1186/1479-5876-9-32
URL : https://hal.archives-ouvertes.fr/inserm-00664981
Cancer Immunotherapy Comes of Age, Journal of Clinical Oncology, vol.29, issue.36, pp.4828-4836, 2011. ,
DOI : 10.1200/JCO.2011.38.0899
organizers: Focus on the Target: The Tumor Microenvironment ,
Tumor Promotion via Injury- and Death-Induced Inflammation, Immunity, vol.35, issue.4, pp.467-477, 2011. ,
DOI : 10.1016/j.immuni.2011.09.006
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis, Cell, vol.124, issue.2, pp.263-266, 2006. ,
DOI : 10.1016/j.cell.2006.01.007
T cell concentration determines their efficiency in killing cognate antigen???expressing syngeneic mammalian cells in vitro and in mouse tissues, The Journal of Experimental Medicine, vol.46, issue.1, pp.223-235, 2010. ,
DOI : 10.1016/0022-1759(86)90079-7
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer, New England Journal of Medicine, vol.353, issue.25, pp.2654-2666, 2005. ,
DOI : 10.1056/NEJMoa051424
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome, Science, vol.313, issue.5795, pp.1960-1964, 2006. ,
DOI : 10.1126/science.1129139
Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction, Journal of Clinical Oncology, vol.29, issue.6, pp.610-618, 2011. ,
DOI : 10.1200/JCO.2010.30.5425
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival, The Journal of Pathology, vol.5, issue.3, pp.389-400, 2011. ,
DOI : 10.1002/path.2866
Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small Cell Lung Cancer, Journal of Thoracic Oncology, vol.5, issue.5, pp.585-590, 2010. ,
DOI : 10.1097/JTO.0b013e3181d60fd7
Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer, Cancer Immunology, Immunotherapy, vol.112, issue.7, pp.909-918, 2011. ,
DOI : 10.1007/s00262-011-1046-y
Gene Signature in Melanoma Associated With Clinical Activity, The Cancer Journal, vol.16, issue.4, pp.399-403, 2010. ,
DOI : 10.1097/PPO.0b013e3181eacbd8
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness, Cancer Res, vol.62, pp.3581-3586, 2001. ,
An immunologic portrait of cancer, Journal of Translational Medicine, vol.9, issue.1, p.146, 2011. ,
DOI : 10.1158/1078-0432.CCR-08-3323
Toll-like receptor 4???dependent contribution of the immune system to anticancer chemotherapy and radiotherapy, Nature Medicine, vol.289, issue.9, pp.1050-1059, 2007. ,
DOI : 10.1038/nm1622
URL : https://hal.archives-ouvertes.fr/hal-00316924
Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy, Clin Cancer Res, vol.7, pp.3025-3030, 2001. ,
Augmented HER-2 Specific Immunity during Treatment with Trastuzumab and Chemotherapy, Clinical Cancer Research, vol.13, issue.17, pp.5133-5143, 2007. ,
DOI : 10.1158/1078-0432.CCR-07-0507
http://www.translational-medicine.com/content, Journal of Translational Medicine, vol.1010, issue.1, p.7070, 2012. ,
T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival, British Journal of Cancer, vol.23, issue.3, pp.366-371, 2011. ,
DOI : 10.1038/nri1936
Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer, Cancer Research, vol.71, issue.4, pp.1263-1271, 2011. ,
DOI : 10.1158/0008-5472.CAN-10-2907
Blockade of ??5??1 Integrins Reverses the Inhibitory Effect of Tenascin on Chemotaxis of Human Monocytes and Polymorphonuclear Leukocytes Through Three-Dimensional Gels of Extracellular Matrix Proteins, The Journal of Immunology, vol.166, issue.12, pp.7534-7542, 2001. ,
DOI : 10.4049/jimmunol.166.12.7534
TNM Staging in Colorectal Cancer: T Is for T Cell and M Is for Memory, Journal of Clinical Oncology, vol.29, issue.6, pp.601-603, 2011. ,
DOI : 10.1200/JCO.2010.32.9078
BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma, Modern Pathology, vol.451, issue.5, p.1 ,
DOI : 10.1038/modpathol.2011.211
Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer, pp.1253-1264, 2011. ,
Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer, Cancer, vol.18, issue.suppl 1, pp.4318-4325, 2010. ,
DOI : 10.1002/cncr.25333
Tumor Antigen???Targeted, Monoclonal Antibody???Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape, Journal of Clinical Oncology, vol.28, issue.28, pp.4390-4399, 2010. ,
DOI : 10.1200/JCO.2009.27.6360
Driving effective tumor immunity with combinatorial immunotherapy, American Society of Clinical Oncology 2010 Educational Book. Edited by: Govindan R, pp.460-465 ,
Antibody association with HER-2/neu???targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs, Journal of Clinical Investigation, vol.118, issue.5, pp.1700-1711, 2008. ,
DOI : 10.1172/JCI34333
Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function, Clin Cancer Res, vol.5, pp.2963-2970, 1999. ,
The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies, Cancer Research, vol.69, issue.6, pp.2514-2522, 2009. ,
DOI : 10.1158/0008-5472.CAN-08-4709
Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients, Clinical Cancer Research, vol.15, issue.6, pp.2148-2157, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-1332
A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism, Clinical Cancer Research, vol.13, issue.13, pp.3951-3959, 2007. ,
DOI : 10.1158/1078-0432.CCR-07-0374
Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between V??9V??2 T Cells, ???? CD8+ T Cells, Regulatory T Cells, and Dendritic Cells, The Journal of Immunology, vol.187, issue.4, pp.1578-1590, 2011. ,
DOI : 10.4049/jimmunol.1002514
Tumour macrophages as potential targets of bisphosphonates, Journal of Translational Medicine, vol.9, issue.1, pp.177-180, 2011. ,
DOI : 10.1023/A:1013026313647
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-723, 2010. ,
DOI : 10.1056/NEJMoa1003466
Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy, Cancer, vol.101, issue.1, pp.67-74, 2006. ,
DOI : 10.1002/cncr.21956
-Specific Vaccination in Patients With Metastatic Breast Cancer, Journal of Clinical Oncology, vol.27, issue.28, pp.4685-4692, 2009. ,
DOI : 10.1200/JCO.2008.20.6789
URL : https://hal.archives-ouvertes.fr/inserm-00691923
A feasibility study of combination therapy with trastuzumab (T), cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumor vaccine for the treatment of HER2+ metastatic breast cancer., Journal of Clinical Oncology, vol.29, issue.15_suppl, p.2535, 2011. ,
DOI : 10.1200/jco.2011.29.15_suppl.2535
Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment, Clinical Cancer Research, vol.11, issue.15, pp.5515-5525, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-0464
Phase I Study of Single-Agent Anti???Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates, Journal of Clinical Oncology, vol.28, issue.19, pp.3167-3175, 2010. ,
DOI : 10.1200/JCO.2009.26.7609
Signaling Through OX40 Enhances Antitumor Immunity, Seminars in Oncology, vol.37, issue.5, pp.524-532, 2010. ,
DOI : 10.1053/j.seminoncol.2010.09.013
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans, Science, vol.331, issue.6024, pp.401612-1616, 2011. ,
DOI : 10.1126/science.1198443
Circumventing Immune Tolerance Through Epigenetic Modification, Current Pharmaceutical Design, vol.16, issue.3, pp.268-276, 2010. ,
DOI : 10.2174/138161210790170120